Sormani MP, Häring DA, Kropshofer H, et al. Blood NfL as a potential endpoint in Phase 2 clinical studies in relapsing-remitting multiple sclerosis. ECTRIMS 2017, 277.
Subcutane toediening kan leiden tot lagere concentraties natalizumab in bloed
feb 2023 | Multipele Sclerose